Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments

被引:18
作者
Aubrey, N
Muzard, J
Peter, JC
Rochat, H
Goyffon, M
Devaux, C
Billiald, P
机构
[1] Museum Natl Hist Nat, USM 0505, F-75231 Paris 05, France
[2] Fac Med Nord, CNRS, UMR 6560, F-13916 Marseille 20, France
[3] Inst Biol Mol & Cellulaire, CNRS, UPR 9021, F-67084 Strasbourg, France
[4] INRA, UMR Univ, Fac Pharm, F-37200 Tours, France
关键词
antivenom; Androctonus australis; antibody engineering; scorpion; toxin; immunotherapy;
D O I
10.1016/j.toxicon.2003.11.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antibody-based therapy is the only specific treatment for scorpion envenomation. However, there are still major drawbacks associated with its use; mainly because antivenoms are still prepared from immune equine serum raised against crude venoms, whereas only a limited number of neurotoxins are responsible for the lethality of the venom. Using a murine hybridoma that secretes a well-characterized neutralizing IgG directed to neurotoxins AahI and AahIII from the venom of the scorpion Androctonus australis, we constructed a recombinant Fab (rFab) fragment, which was produced and purified from transformed bacteria. It recognized toxin Aahl with a high affinity (K-D = 8.2 X 10(-11) M) equivalent to the homologous pFab prepared by papain digestion of whole IgG. Although the AahI-neutralizing capacity of protein L-purified rFab was low compared to other recombinant antibody formats (scFv and diabody) investigated in parallel, the antibody engineering approach presented here provides an innovative way to synthesize novel toxin-neutralizing molecules. It may serve as a strategy for designing a new generation of antivenoms. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 39 条
[1]   Serotherapy in scorpion envenomation: a randomised controlled trial [J].
Abroug, F ;
ElAtrous, S ;
Nouira, S ;
Haguiga, H ;
Touzi, N ;
Bouchoucha, S .
LANCET, 1999, 354 (9182) :906-909
[2]   Methods for the generation of chicken monoclonal antibody fragments by phage display [J].
Andris-Widhopf, J ;
Rader, C ;
Steinberger, P ;
Fuller, R ;
Barbas, CF .
JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 242 (1-2) :159-181
[3]   Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin [J].
Aubrey, N ;
Devaux, C ;
Sizaret, PY ;
Rochat, H ;
Goyffon, M ;
Billiald, P .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (03) :617-628
[4]   A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin Aahl [J].
Aubrey, N ;
Devaux, C ;
di Luccio, E ;
Goyffon, M ;
Rochat, H ;
Billiald, P .
BIOLOGICAL CHEMISTRY, 2001, 382 (11) :1621-1628
[5]   Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity [J].
Boder, ET ;
Midelfort, KS ;
Wittrup, KD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (20) :10701-10705
[6]  
BOND GR, 1992, ANN EMERG MED, V21, P788, DOI 10.1016/S0196-0644(05)81022-4
[7]   Therapeutic antibody fragments with prolonged in vivo half-lives [J].
Chapman, AP ;
Antoniw, P ;
Spitali, M ;
West, S ;
Stephens, S ;
King, DJ .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :780-783
[8]   Venoms, antivenoms and immunotherapy [J].
Chippaux, JP ;
Goyffon, M .
TOXICON, 1998, 36 (06) :823-846
[9]   Monoclonal antibodies against the Androctonus australis hector scorpion neurotoxin I:: characterisation and use for venom neutralisation [J].
Clot-Faybesse, O ;
Juin, M ;
Rochat, H ;
Devaux, C .
FEBS LETTERS, 1999, 458 (03) :313-318
[10]   Validation of biopharmaceutical purification processes for virus clearance evaluation [J].
Darling, A .
MOLECULAR BIOTECHNOLOGY, 2002, 21 (01) :57-83